{"organizations": [], "uuid": "e3adfd234fe7312ee2ea0423e5929f098dd8e4c7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s4.reutersmedia.net/resources/r/?d=20180328&i=OV88WO3NV&w=1200&r=OV88WO3NV&t=2", "site_section": "http://feeds.reuters.com/reuters/UKVideoLatest", "section_title": "Reuters Video: Latest Videos UK", "url": "https://uk.reuters.com/video/2018/03/28/japans-takeda-considers-possible-40-bln?videoId=412854188", "country": "US", "domain_rank": 408, "title": "Japan's Takeda considers possible $40 bln bid for Shire", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-28T18:12:00.000+03:00", "replies_count": 0, "uuid": "e3adfd234fe7312ee2ea0423e5929f098dd8e4c7"}, "author": "", "url": "https://uk.reuters.com/video/2018/03/28/japans-takeda-considers-possible-40-bln?videoId=412854188", "ord_in_thread": 0, "title": "Japan's Takeda considers possible $40 bln bid for Shire", "locations": [], "entities": {"persons": [{"name": "david pollard", "sentiment": "none"}], "locations": [{"name": "japan", "sentiment": "none"}], "organizations": [{"name": "shire japan", "sentiment": "negative"}, {"name": "bst", "sentiment": "negative"}, {"name": "shire", "sentiment": "negative"}, {"name": "takeda", "sentiment": "negative"}, {"name": "takeda pharmaceutical", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Japan's Takeda considers possible $40 bln bid for Shire 5:01pm BST - 01:13 \nJapan's largest drugmaker Takeda Pharmaceutical is considering a bid for London-listed Shire that could top $40 billion and spark another takeover battle in the deal-hungry pharma industry. David Pollard reports.   \nJapan's largest drugmaker Takeda Pharmaceutical is considering a bid for London-listed Shire that could top $40 billion and spark another takeover battle in the deal-hungry pharma industry. David Pollard reports.  //reut.rs/2pICviL", "external_links": [], "published": "2018-03-28T18:12:00.000+03:00", "crawled": "2018-03-28T20:13:04.009+03:00", "highlightTitle": ""}